Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus Krüger

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Zeitschrift Fur Rheumatologie|June 16, 2021
[Does methotrexate influence the efficacy of vaccination against SARS-CoV-2?]Klaus Krüger,
Zeitschrift Fur Rheumatologie|February 9, 2023
[DMARD (disease-modifying antirheumatic drug) treatment in patients with former or current cancer]Klaus Krüger
Zeitschrift Fur Rheumatologie|January 8, 2022
[Innovative strategies for treatment of rheumatoid arthritis]Klaus Krüger
Deutsches Arzteblatt International|August 22, 2013
Rheumatoid arthritis--early diagnosis and disease managementMatthias Schneider, Klaus Krüger
Zeitschrift Fur Rheumatologie|December 16, 2020
[Infection prophylaxis in rheumatic diseases]Christian Kneitz, Klaus Krüger
Zeitschrift Fur Rheumatologie|June 3, 2024
[Head-to-head trials in rheumatoid arthritis]Diana Ernst, Klaus Krüger, Torsten Witte
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|July 30, 2016
Evaluating the consequences of rheumatoid arthritisBjörn Sossong, Stefan Felder, Malte Wolff, et al.
Rheumatology and Therapy|April 19, 2020
Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in GermanyKlaus Krüger, Gerd Rüdiger Burmester, Siegfried Wassenberg, et al.
Zeitschrift Fur Rheumatologie|September 21, 2021
[Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis]Udo Schneider, Elise Siegert, Sven Gläser, et al.
Current Medical Research and Opinion|July 2, 2020
Golimumab improves socio economic and health economic parameters in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitisKlaus Krüger, Gerd Rüdiger Burmester, Siegfried Wassenberg, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Zeitschrift Fur Rheumatologie|June 16, 2021
[Does methotrexate influence the efficacy of vaccination against SARS-CoV-2?]Klaus Krüger,
Zeitschrift Fur Rheumatologie|February 9, 2023
[DMARD (disease-modifying antirheumatic drug) treatment in patients with former or current cancer]Klaus Krüger
Zeitschrift Fur Rheumatologie|January 8, 2022
[Innovative strategies for treatment of rheumatoid arthritis]Klaus Krüger
Deutsches Arzteblatt International|August 22, 2013
Rheumatoid arthritis--early diagnosis and disease managementMatthias Schneider, Klaus Krüger
Zeitschrift Fur Rheumatologie|December 16, 2020
[Infection prophylaxis in rheumatic diseases]Christian Kneitz, Klaus Krüger
Zeitschrift Fur Rheumatologie|June 3, 2024
[Head-to-head trials in rheumatoid arthritis]Diana Ernst, Klaus Krüger, Torsten Witte
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|July 30, 2016
Evaluating the consequences of rheumatoid arthritisBjörn Sossong, Stefan Felder, Malte Wolff, et al.
Rheumatology and Therapy|April 19, 2020
Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in GermanyKlaus Krüger, Gerd Rüdiger Burmester, Siegfried Wassenberg, et al.
Zeitschrift Fur Rheumatologie|September 21, 2021
[Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis]Udo Schneider, Elise Siegert, Sven Gläser, et al.
Current Medical Research and Opinion|July 2, 2020
Golimumab improves socio economic and health economic parameters in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitisKlaus Krüger, Gerd Rüdiger Burmester, Siegfried Wassenberg, et al.
Pageof 5